Targeted pharmacodynamic of subtilisins
Abstract
Subtilisin is one of the proteolytic enzymes. It is produced by bacteria of the genus Bacillus subtilis and has great potential in pharmacology of thrombosis. Direct thrombolytic effect and no side effects similar to those of widely used in the last 20 years plasminogen activators lead to this opportunity. Recent studies of the clinical use of subtilisin have shown their effectiveness not only for the treatment of thrombosis, but also for the prevention of cardiovascular disease and dementia. However, the use of subtilisin in medicine is limited by its low bioavailability. Trombovazim® is a new domestic product, wich is based on pegylated subtilisin and created using technology of radiation synthesis. Trombovazim® has targeted thrombolytic, cardioprotective and anti-inflammatory action. Today Trombovazim® is the only registered oral thrombolytic. Immobilized subtilisin are broad prospects for introduction in clinical practice.
Key words
Madonov P.G. – doctor of medical sciences, professor, head of the chair for pharmacology, clinical pharmacology and evidentiary medicine, e-mail: madonov@scpb.ru
Mishenina S.V. – candidate of medical sciences, associated professor of the chair for pharmacology, clinical pharmacology and evidentiary medicine
Kinsht D.N. – doctor of medical sciences, professor, head of the chair for pharmacology, clinical pharmacology and evidentiary medicine
Kikhtenko N.V. – deputy head of research department